| Literature DB >> 20197132 |
Hitoki Yamanaka1, Teri Hoyt, Xinghong Yang, Richard Bowen, Sarah Golden, Kathryn Crist, Todd Becker, Massimo Maddaloni, David W Pascual.
Abstract
The chemokine, lymphotactin (LTN), was tested as a molecular adjuvant using bicistronic DNA vaccines encoding the protective Yersinia capsular (F1) antigen and virulence antigen (V-Ag) as a F1-V fusion protein. The LTN-encoding F1-V or V-Ag vaccines were given by the intranasal (i.n.) or intramuscular (i.m.) routes, and although serum IgG and mucosal IgA antibodies (Abs) were induced, F1-Ag boosts were required for robust anti-F1-Ag Abs. Optimal efficacy against pneumonic plague was obtained in mice i.m.-, not i.n.-immunized with these DNA vaccines. These vaccines stimulated elevated Ag-specific Ab-forming cells and mixed Th cell responses, with Th17 cells markedly enhanced by i.m. immunization. These results show that LTN can be used as a molecular adjuvant to enhance protective immunity against plague. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20197132 PMCID: PMC2861050 DOI: 10.1016/j.vaccine.2010.02.022
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641